Clinical Research Directory
Browse clinical research sites, groups, and studies.
PRA-216 COPD Safety and Biomarker Study
Sponsor: Prana Therapies Inc
Summary
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with chronic obstructive pulmonary disease (COPD).
Official title: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Key Details
Gender
All
Age Range
40 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-08-25
Completion Date
2027-09-01
Last Updated
2026-10-28
Healthy Volunteers
No
Interventions
PRA-216
biologic
Placebo
matching placebo for PRA-216
Locations (5)
Emeritus Research Sydney
Botany, New South Wales, Australia
Campbelltown Hospital
Campbelltown, New South Wales, Australia
University of the Sunshine Coast
Birtinya, Queensland, Australia
Griffith University
Southport, Queensland, Australia
Emeritus Research Camberwell
Camberwell, Victoria, Australia